-
Featured Authors
Business of Biotech
Archive
- June 2013 (2)
- April 2013 (1)
- February 2013 (2)
- January 2013 (1)
- October 2012 (1)
- September 2012 (3)
- August 2012 (1)
- January 2012 (3)
- December 2011 (2)
- October 2011 (3)
- August 2011 (3)
- July 2011 (2)
- June 2011 (12)
- April 2011 (2)
- January 2010 (1)
- November 2009 (1)
- October 2009 (47)
- September 2009 (37)
- August 2009 (1)
- June 2008 (3)
- May 2008 (2)
- April 2008 (1)
- February 2008 (6)
Category Archives: Business of Biotech
A Word with Calistoga Pharmaceuticals’ CEO
An interview with Dr. Carol Gallagher, Pharm.D., CEO of Calistoga Pharmaceuticals: Can you describe the top priorities or upcoming milestones for your company? 4Q 2009: Reporting updated efficacy and safety data from the ongoing CAL-101 Phase 1 trial in patients with hematologic malignancies 1H 2010: Initiating a Phase 2 registration program for CAL-101 Initiating a Phase 2 trial evaluating CAL-263, a novel oral delta isoform-selective PI3K inhibitor, in patients with asthma Initiating a Phase 1 Read More >
XOMA to Repay Goldman Sachs Loan in Full
XOMA Ltd. (Nasdaq:XOMA) announced a plan to repay its loan with Goldman Sachs Specialty Holdings, Inc. (Goldman Sachs) through a combination of funds. Payment will include proceeds from Genentech’s payment to XOMA for the buyout of its LUCENTIS(R) royalty obligation to XOMA, the sale of common stock and funds from an existing restricted cash account reserved for loan repayment. The repayment plan resolves the uncertainty about the loan that arose from the sudden and unexpected Read More >
Newron Announces Positive Results for Ralfinamide
Newron Pharmaceuticals SpA, announced positive preclinical study results showing that ralfinamide has statistically significant benefits against spontaneous chronic pain in an experimental model of central pain. Ralfinamide has shown positive results in chronic pain on CNS targets, in addition to its known peripheral mechanisms; Ralfinamide’s unique ability to affect central targets widens its broad spectrum of analgesic mechanisms, supporting its therapeutic potential for alleviating Neuropathic Low Back Pain (NLBP) in the ongoing SERENA Phase IIb/III Read More >
Flu Study Finds Only One H1N1 Vaccine Shot Needed
Early results from clinical trials show that the majority of healthy adults may only need one vaccine shot rather than two to protect against the H1N1 virus. Results are showing that the effects of the vaccine are starting faster than expected. Those results could mean that the limited vaccine supply, with an estimated 45 million doses to be made available next month because of poorer-than-expected yields from growing the virus in chicken eggs, could be Read More >
Team at BrainCells using brain cells
An interview with James A. Schoeneck, Chief Executive Officer, BrainCells, Inc.: Can you describe the top priorities or upcoming milestones for your company? BrainCells Inc. has two up-coming milestones in 1Q10: the advancement of BCI-632 into a Phase 1 clinical trial, and Phase 2 data for BCI-540 in patients with treatment resistant depression and anxiety. Both compounds have novel mechanisms of action. In July, the company announced the outcome of an exploratory Phase 2 study Read More >
